

附件 4 主要论著目录

4.1 论文

4.1.1 通讯（含共同）作者论文

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, **Wu G**, Gao GF, Tan W, China Novel Coronavirus I, Research T. 2020. A Novel Coronavirus from Patients with Pneumonia in China. *N Engl J Med*, 382(2019), 727-733, doi: 10.1056/NEJMoa2001017.
2. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, **Wu G**, Chen W, Shi W, Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet*, 395(10224)(2020), p. 565-574, doi: 10.1016/S0140-6736(20)30251-8.
3. Bao L, Deng W, Huang B, Gao H, Liu J, Ren L, Wei Q, Yu P, Xu Y, Qi F, Qu Y, Li F, Lv Q, Wang W, Xue J, Gong S, Liu M, Wang G, Wang S, Song Z, Zhao L, Liu P, Zhao L, Ye F, Wang H, Zhou W, Zhu N, Zhen W, Yu H, Zhang X, Guo L, Chen L, Wang C, Wang Y, Wang X, Xiao Y, Sun Q, Liu H, Zhu F, Ma C, Yan L, Yang M, Han J, Xu W, Tan W, Peng X, Jin Q, **Wu G**, Qin C. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. *Nature*, 583(7818)(2020), p. 830-833, doi: 10.1038/s41586-020-2312-y.
4. Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B, Liu R, He X, Shuai L, Sun Z, Zhao Y, Liu P, Liang L, Cui P, Wang J, Zhang X, Guan Y, Tan W, **Wu G**, Chen H, Bu Z. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. *Science*, 368(6494)(2020), p. 1016-1020, doi: 10.1126/science.abb7015.
5. Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J, Liang H, Bao L, Xu Y, Ding L, Zhou W, Gao H, Liu J, Niu P, Zhao L, Zhen W, Fu H, Yu S, Zhang Z, Xu G, Li C, Lou Z, Xu M, Qin C, **Wu G**, Gao GF, Tan W, Yang X. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. *Cell*, 182(3)(2020), p. 713-721.e9, doi: 10.1016/j.cell.2020.06.008.
6. Liu WJ, Liu P, Lei W, Jia Z, He X, Shi W, Tan Y, Zou S, Wong G, Wang J, Wang F, Wang G, Qin K, Gao R, Zhang J, Li M, Xiao W, Guo Y, Xu Z, Zhao Y, Song J, Zhang J, Zhen W, Zhou W, Ye B, Song J, Yang M, Zhou W, Dai Y, Lu G, Bi Y, Tan W, Han J, Gao GF, **Wu G**. Surveillance of SARS-CoV-2 at the Huanan

Seafood Market. *Nature*, 2023 Apr 5, doi: 10.1038/s41586-023-06043-2.

7. Liu WJ, Lei W, He X, Liu P, Wang Q, Wu Z, Tan Y, Song S, Wong G, Lu J, Jiang J, Wei Q, Li M, Ma J, Peng X, Li Y, Huang B, Tong Y, Han J, **Wu G**. Back to Science in Searching for SARS-CoV-2 Origins. *China CDC Wkly*, 5(14)(2023), 315-317, doi: 10.46234/ccdcw2023.055.
8. Wang X, Xie Y, Liu H, Lei W, Xu K, Wu L, Fan R, **Wu G**, Gao GF, Wang Q. A broadly neutralizing nanobody targeting the highly conserved S2 subunit of sarbecoviruses. *Sci Bull*, 68(7)(2023), 684-687, doi: 10.1016/j.scib.2023.03.027.
9. Liu H, Wu L, Liu B, Xu K, Lei W, Deng J, Rong X, Du P, Wang L, Wang D, Zhang X, Su C, Bi Y, Chen H, Liu WJ, Qi J, Cui Q, Qi S, Fan R, Jiang J, **Wu G**, Gao GF, Wang Q. Two pan-SARS-CoV-2 nanobodies and their multivalent derivatives effectively prevent Omicron infections in mice. *Cell Rep Med*, 4(2)(2023), 100918, doi: 10.1016/j.xcrm.2023.100918.
10. Yang Dou, Ke Xu, Yong-Qiang Deng, Zijing Jia, Jun Lan, Xiaoyu Xu, Guorui Zhang, Tianshu Cao, Pan Liu, Xiangxi Wang, Xinquan Wang, Lingjie Xu, Pan Du, Cheng-Feng Qin, Hong Liu, Yafeng Li, **Wu G**, Kang Wang, Bai Lu. Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method. *Antib Ther*, 6(2)(2023), 76-86, doi: 10.1093/abt/tbad002.
11. Xu K, Lei W, Kang B, Yang H, Wang Y, Lu Y, Lv L, Sun Y, Zhang J, Wang X, Yang M, Dan M, **Wu G**. A novel mRNA vaccine, SYS6006, against SARS-CoV-2. *Front Immunol*, 13(2023), 1051576, doi: 10.3389/fimmu.2022.1051576.
12. Kaabi NA, Yang YK, Liang Y, Xu K, Zhang XF, Kang Y, Jin YQ, Hou JW, Zhang J, Yang T, Hussein S, ElDein MS, Lei ZH, Zhang H, Shao S, Liu ZM, Liu N, Zheng X, Su JG, Yang SS, Cong X, Tan Y, Lei W, Gao XJ, Jiang Z, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Xiao P, Shen FJ, Wu JJ, Han ZB, Du LF, Tang F, Chen S, Ma ZJ, Zheng F, Hou YN, Li XY, Li X, Wang ZN, Yin JL, Mao XY, Zhang J, Qu L, Zhang YT, Yang XM, **Wu G**, Li QM. Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial. *Signal Transduct Target Ther*, 8(1)(2023), 20, doi: 10.1038/s41392-022-01295-2.
13. Yin J, Zhao Y, Huang F, Yang Y, Huang Y, Zhuang Z, Wang Y, Wang Z, Lin X, Zheng Y, Zhou W, Wang S, Xu Z, Ye B, Guo Y, Lei W, Li L, Tian J, Gan J, Wang H, Wang W, Ma P, Liu C, Wei X, Shi X, Wang Z, Wang Y, Liu Y, Yang M, Yuan Y, Song Y, Ma W, Huang Z, Liu Y, Huang Y, Lu H, Liu P, Liang H, Hou Y, Xu X, Liu L, Zhang Y, **Wu G**, Gao GF, Jin X, Liu C, Yang X, Liu WJ. Immune response

- and homeostasis mechanism following administration of BBIBP-CorV SARS-CoV-2 inactivated vaccine. *Innovation (Camb)*, 4(1)(2023), 100359, doi: 10.1016/j.xinn.2022.100359.
14. Xu K, Gao P, Liu S, Lu S, Lei W, Zheng T, Liu X, Xie Y, Zhao Z, Guo S, Tang C, Yang Y, Yu W, Wang J, Zhou Y, Huang Q, Liu C, An Y, Zhang R, Han Y, Duan M, Wang S, Yang C, Wu C, Liu X, She G, Liu Y, Zhao X, Xu K, Qi J, **Wu G**, Peng X, Dai L, Wang P, Gao GF. Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. *Cell*, 185(13)(2022), 2265-2278.e14, doi: 10.1016/j.cell.2022.04.029.
 15. Kaabi NA, Yang YK, Zhang J, Xu K, Liang Y, Kang Y, Su JG, Yang T, Hussein S, ElDein MS, Shao S, Yang SS, Lei W, Gao XJ, Jiang Z, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Xiao P, Wang ZN, Yin JL, Mao XY, Zhang J, Liu N, Shen FJ, Qu L, Zhang YT, Yang XM, **Wu G**, Li QM. Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial. *Signal Transduct Target Ther*, 7(1)(2022), 172, doi: 10.1038/s41392-022-00984-2.
 16. Kaabi NA, Yang YK, Du LF, Xu K, Zhang YT, Yang XM, **Wu G**, Li QM, etc., Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial. *Nat Commun*, 13(1)(2022), 3654, doi: 10.1038/s41467-022-31379-0.
 17. Liang Y, Zhang J, Yuan RY, Wang MY, He P, Su JG, Han ZB, Jin YQ, Hou JW, Zhang H, Zhang XF, Shao S, Hou YN, Liu ZM, Du LF, Shen FJ, Zhou WM, Xu K, Gao RQ, Tang F, Lei ZH, Liu S, Zhen W, Wu JJ, Zheng X, Liu N, Chen S, Ma ZJ, Zheng F, Ren SY, Hu ZY, Huang WJ, **Wu G**, Ke CW, Li QM. Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2. *Cell Discov*, 8(1)(2022), 17, doi: 10.1038/s41421-022-00383-5.
 18. Zhang Y, Tan W, Lou Z, Zhao Y, Zhang J, Liang H, Li N, Zhu X, Ding L, Huang B, Zhou W, Guo Y, Yang Z, Qiao Y, He Z, Ma B, He Y, Zhu D, Wang Z, Chang Z, Zhao X, Wang W, Xu Y, Zhu H, Zheng X, Wang C, Xu G, **Wu G**, Wang H, Yang X. Vaccination with Omicron Inactivated Vaccine in Pre-vaccinated Mice Protects against SARS-CoV-2 Prototype and Omicron Variants. *Vaccines (Basel)*, 10(7)(2022), 1149, doi: 10.3390/vaccines10071149.
 19. Zhang Y, Xu X, Yu L, Shi X, Min M, Xiong L, Pan J, Zhang Y, Liu P, **Wu G**, Gao G. Vaginal Microbiota Changes Caused by HPV Infection in Chinese Women. *Front Cell Infect Microbiol*, 12(2022), 814668, doi: 10.3389/fcimb.2022.814668.
 20. Kaabi NA, Yang YK, Du LF, Xu K, Shao S, Liang Y, Kang Y, Su JG, Zhang J, Yang T, Hussein S, ElDein MS, Yang SS, Lei W, Gao XJ, Jiang Z, Cong X, Tan Y, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Hou JW, Lei ZH, Xiao P, Wang ZN, Yin JL, Mao XY, Zhang J, Qu L, Zhang YT, Yang XM, **Wu G**, Li QM. Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial. *Nat Commun*, 13(1)(2022), 3654, doi: 10.1038/s41467-022-31379-0.
 21. Zhang Y, Tan W, Lou Z, Huang B, Zhou W, Zhao Y, Zhang J, Liang H, Li N, Zhu

- X, Ding L, Guo Y, He Z, He Y, Wang Z, Ma B, Ma M, Zhao S, Chang Z, Zhao X, Zheng X, **Wu G**, Wang H, Yang X. Immunogenicity Evaluating of the Multivalent COVID-19 Inactivated Vaccine against the SARS-CoV-2 Variants. *Vaccines (Basel)*, 10(6)(2022), 956, doi: 10.3390/vaccines10060956.
22. Lin H, Zhang J, Dong S, Liu Y, Liu P, Gao GF, Liu WJ, **Wu G**. An adjusted ELISpot-based immunoassay for evaluation of SARS-CoV-2-specific T-cell responses. *Biosaf Health*, 4(3)(2022), 179-185, doi: 10.1016/j.bsheal.2022.04.005.
23. Yu Y, Ding J, Zhou Y, Xiao H, **Wu G**. Biosafety chemistry and biosafety materials: A new perspective to solve biosafety problems. *Biosaf Health*, 4(1)(2022), 15-22, doi: 10.1016/j.bsheal.2022.01.001.
24. Zhang J, Lin H, Ye B, Zhao M, Zhan J, Dong S, Guo Y, Zhao Y, Li M, Liu S, Zhang H, Xiao W, Guo Y, Yue C, Zhang D, Yang M, Zhang J, Quan C, Shi W, Liu X, Liu P, Jiang Y, **Wu G**, Gao GF, Liu WJ. One-year sustained cellular and humoral immunities of COVID-19 convalescents. *Clin Infect Dis*, 75(1)(2022), e1072-e1081, doi: 10.1093/cid/ciab884.
25. Xu X, Zhang Y, Yu L, Shi X, Min M, Xiong L, Pan J, Liu P, **Wu G**, Gao G. A cross-sectional analysis about bacterial vaginosis, high-risk human papillomavirus infection, and cervical intraepithelial neoplasia in Chinese women. *Sci Rep*, 12(1)(2022), 6609, doi: 10.1038/s41598-022-10532-1.
26. Chen Q, Huang XY, Tian Y, Fan C, Sun M, Zhou C, Li R, Zhang RR, **Wu G**, Qin CF. The Infection and Pathogenicity of SARS-CoV-2 Variant B.1.351 in hACE2 Mice. *Virol Sin*, 36(5)(2021), 1232-1235, doi: 10.1007/s12250-021-00452-1.
27. Zhao L, Gao R, Lu R, Wang H, Deng Y, Niu P, Jiang F, Huang B, Liang J, Jia J, Zhang F, Wang W, **Wu G**, Tan W. Profiles of SARS-CoV-2 RNA and Antibodies in Inpatients with COVID-19 not Related with Clinical Manifestation: A Single Centre Study. *Virol Sin*, 36(5)(2021), 1088-1092, doi: 10.1007/s12250-021-00411-w.
28. Guo Y, Liu P, Zhang L, Peng S, Wang X, Luo H, **Wu G**. Disinfection of *Escherichia coli* in ice by surface dielectric barrier discharge plasma. *Appl Phys Lett*, 119(9)(2021), 090601, doi: 10.1063/5.0064020.
29. Yuanyuan Guo, William J. Liu, Jingdong Song, Kexin Zong, Hao Lin, Xin Li, Shuting Huo, Sai Liu, Hongli Ran, Hongmei Li, Peipei Liu, He Huang, George F. Gao, **Wu G**. Parallel isolation of calicivirus and reovirus from lethal co-infected mink during a potential epidemic of farmed mink infections, *Biosafety and Health*, 2021, ISSN 2590-0536, doi:org/10.1016/j.bsheal.2021.08.002.
30. Su, Qiu-Dong, Zou, Ye-Ning, Yi, Yao, Shen, Li-Ping, Ye, Xiang-Zhong, Zhang, Yang, Wang, Hui,Ke, Hong,Song, Jing-Dong,Hu, Ke-Ping,Cheng, Bo-Lin,Qiu, Feng,Yu, Peng-Cheng,Zhou, Wen-Ting,Zhao, Ran,Cao, Lei,Dong, Gao-Feng,Bi, Sheng-Li, **Wu G**, Gao, George Fu, Zheng, Jerry. Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces, strong neutralization antibody response. *Vaccine*, 39(8)(2021), 1241-1247, doi: 10.1016/j.vaccine.2021.01.044.
31. Zhang, KY, Hong, M, Zhang, Y, Han, ZZ, Xiao, JB, Lu, HH, Song, Y, Yan, DM, Wang, DY, Zhu, SL, Xu, WB, **Wu G**. Molecular Epidemiological, Serological,

- and Pathogenic Analysis of EV-B75 Associated With Acute Flaccid Paralysis Cases in Tibet, China. *Front Microbiol*, 11(2021), 632552, doi: 10.3389/fmicb.2020.632552, WOS:00061207780000.
32. Zhang Y, Pan Y, Zhao X, Shi W, Chen Z, Zhang S, Liu P, Xiao J, Tan W, Wang D, Liu WJ, Xu W, Wang Q, **Wu G**. 2020. Genomic characterization of SARS-CoV-2 identified in a reemerging COVID-19 outbreak in Beijing's Xinfadi market in 2020. *Biosaf Health*, 2(4)(2020), 202-205, doi: 10.1016/j.bsheal.2020.08.006.
 33. Zhang Y, Chen C, Song Y, Zhu S, Wang D, Zhang H, Han G, Weng Y, Xu J, Xu J, Yu P, Jiang W, Yang X, Lang Z, Yan D, Wang Y, Song J, Gao GF, **Wu G**, Xu W. 2020. Excretion of SARS-CoV-2 through faecal specimens. *Emerg Microbes Infect*, 9(1)(2020), 2501-2508, doi: 10.1080/22221751.2020.1844551.
 34. Fan GH, Shen XX, Li F, Li XN, Bai XD, Zhang RQ, Wang RH, Lei WW, Wang HY, Ma XJ, **Wu G**. Development of an Internally Controlled Reverse Transcription Recombinase-aided Amplification Assay for the Rapid and Visual Detection of West Nile Virus. *Biomed Environ Sci*, 32(12)(2019), 926-929, doi: 10.3967/bes2019.116.
 35. Zhang Y, Ye F, Xia LX, Zhu LW, Kamara IL, Huang KQ, Zhang Y, Liu J, Kargbo B, Wang J, Liang MF, Song JD, Ma XJ, **Wu G**. Next-generation Sequencing Study of Pathogens in Serum from Patients with Febrile Jaundice in Sierra Leone. *Biomed Environ Sci*, 32(5)(2019), 363-370, doi: 10.3967/bes2019.048.
 36. Yu PC, Tao XY, Wang LH, Tang Q, Fan LY, Zhang SX, Liu SQ, Lu XX, **Wu G**, Zhu WY. 2018. Establishment of a Chinese street rabies virus library and its application for detecting neutralizing activity. *Infect Dis Poverty*, 7(1)(2018), 117, doi: 10.1186/s40249-018-0500-x.
 37. Song J, Zhou W, Wang Y, Cui Y, Huang XX, Zhang BY, **Wu G**, Han J, Dong XP. 2012. Contamination of Live Virus during Tissue Homogenizing by Ultrasonic Processor and Tissue Disperser. *Biomed Environ Sci*, 25(2)(2012), 167-71, doi: 10.3967/0895-3988.2012.02.007.
 38. Han Y, Liu P, Qiu Y, Zhou J, Liu Y, Hu X, Yang Q, Huang R, Wen X, Song H, Yu P, Yang M, Zhang J, Liu WJ, Peng K, **Wu G**, Zhang D, Zhou X, Wu Y. Effective virus-neutralizing activities in antisera from the first wave of severe COVID-19 survivors. *JCI Insight*, 6(4)(2021), e146267, doi: 10.1172/jci.insight.146267.
 39. Hu M, Lin H, Wang J, Xu C, Tatem AJ, Meng B, Zhang X, Liu Y, Wang P, **Wu G**, Xie H, Lai S. Risk of Coronavirus Disease 2019 Transmission in Train Passengers: an Epidemiological and Modeling Study. *Clin Infect Dis*, 72(4)(2021), 604-610, doi: 10.1093/cid/ciaa1057.
 40. Liu WJ, **Wu G**. Convincing the confidence to conquer COVID-19: From epidemiological intervention to laboratory investigation. *Biosaf Health*, 2(4)(2020), 185-186, doi: 10.1016/j.bsheal.2020.11.005.
 41. Liu P, Yang M, Zhao X, Guo Y, Wang L, Zhang J, Lei W, Han W, Jiang F, Liu WJ, Gao GF, **Wu G**. Cold-chain transportation in the frozen food industry may have caused a recurrence of COVID-19 cases in destination: Successful isolation of SARS-CoV-2 virus from the imported frozen cod package surface. *Biosafe Health*, 2(4)(2022), 9-201, doi: 10.1016/j.bsheal.2020.11.003.

42. Su QD, Yi Y, Zou YN, Jia ZY, Qiu F, Wang F, Yin WJ, Zhou WT, Zhang S, Yu PC, Bi SL, Shen LP, **Wu G**. The biological characteristics of SARS-CoV-2 spike protein Pro330-Leu650. *Vaccine*, 38(32)(2020), 5071-5075, doi: 10.1016/j.vaccine.2020.04.070.
43. Li J, Yan D, Chen L, Zhang Y, Song Y, Zhu S, Ji T, Zhou W, Gan F, Wang X, Hong M, Guan L, Shi Y, **Wu G**, Xu W. Multiple genotypes of Echovirus 11 circulated in mainland China between 1994 and 2017. *Sci Rep*, 9(1)(2019), 10583, doi: 10.1038/s41598-019-46870-w.
44. Wang J, Zhou W, Ling H, Dong X, Zhang Y, Li J, Zhang Y, Song J, Liu WJ, Li Y, Zhang R, Zhen W, Cai K, Zhu S, Wang D, Xiao J, Tong Y, Liu W, Song L, Wu W, Liu Y, Zhao X, Wang R, Ye S, Wang J, Lu R, Huang B, Ye F, Lei W, Gao R, Shi Q, Chen C, Han J, Xu W, Gao GF, Ma X, **Wu G**. Identification of Histoplasma causing an unexplained disease cluster in Matthews Ridge, Guyana. *Biosaf Health*, 1(3)(2019), 150-154, doi: 10.1016/j.bsheal.2019.12.003.
45. Lu X, Zhu W, **Wu G**, Rabies virus transmission via solid organs or tissue allotransplantation. *Infect Dis Poverty*, 7(1)(2018), 82, doi: 10.1186/s40249-018-0467-7.
46. Wang Q, Zhou W, Zhang Y, Wang H, Du H, Nie K, Song J, Xiao K, Lei W, Guo J, Wei J, Cai K, Wang H, Wu J, Kamara G, Kamara I, Wei Q, Liang F, **Wu G**, Dong X. Good laboratory practices guarantee biosafety in the Sierra Leone-China friendship biosafety laboratory. *Infect Dis Poverty*, 5(1)(2016), 62, doi: 10.1186/s40249-016-0154-5.
47. Song J, Zhou W, Wang Y, Cui Y, Huang X, Zhang B, **Wu G**, Han J, Dong X. Contamination of live virus during tissue homogenization with ultrasonic processor and tissue disperser. *Biomed Environ Sci*, 25 (2)(2012), 56-61, doi: 10.3967/0895-3988.2012.02.007.
48. Lin H, Liu X, Sun H, Zhang J, Dong S, Liu M, Li L, Tian J, Guo Y, Gan J, Chen Z, Wang X, Lin Y, Zhang D, Liu Y, Zhang X, Liu P, Xu K, Zhou X, Liang H, Gao GF, Liu WJ, **Wu G**. Sustained abnormality with recovery of COVID-19 convalescents: a 2-year follow-up study. *SciBull(Beijing)*. 2022 Aug 15, 67(15), 1556-1561, doi: 10.1016/j.scib.2022.06.025.Epub2022Jun30.
49. 刘培培, 江佳富, 路浩, 丛培蕾, 赵莉藺, 乔格侠, 周冬生, **武桂珍**. 加快推进生物安全能力建设, 全力保障国家生物安全[J]. *中国科学院院刊*, 38(03)(2023), 414-423.
50. 乔佩雯, 岳灿, 霍恕婷, 刘科芳, 李敏, 郭雅欣, 高国兰, 刘军, **武桂珍**. 猫MHC I类分子呈递的SARS-CoV-2来源多肽筛选及其复合物晶体制备 [J]. *国际病毒学杂志*, 28(2)(2021), 120-125.
51. 杨梦婕, 徐玲丽, 马学军, **武桂珍**. 肉及肉制品中6种致病菌的GeXP多重PCR检测[J]. *食品研究与开发*, 42(13)(2021), 168-173.
52. 甄维, 梁宏阳, 赵雪, 常振, 史海月, 周为民, **武桂珍**. 应用篮式生物反应器在BSL-3实验室进行病毒培养的评估[J]. *中华实验和临床病毒学杂志*, 34(04)(2020), 420-423.

53. 甘芳容, 张焯, 谭敏菊, 成艳辉, 薄洪, 房琼琼, 周为民, 王大燕, 董婕, **武桂珍**. 理化条件对人感染 H9N2 禽流感病毒灭活效果的评价[J]. 中华实验和临床病毒学杂志, (01) (2020), 87-91.
54. 李婕, 严冬梅, 张勇, 许文波, 祝双利, 周为民, **武桂珍**. 肠道病毒 A 组 71 型热力和常见 3 种化学消毒剂灭活效果的研究[J]. 中华实验和临床病毒学杂志, (01)(2020), 18-22.
55. 甄维, 蔡琨, 张靖, 史海月, 周为民, **武桂珍**. 生物安全三级实验室 2 种防护型口罩的定量适合性测试比较[J]. 生物技术通讯, 31(01)(2020), 71-74.
56. 阿茹罕, 王文玲, **武桂珍**. 公卫先行“十三五”国家传染病重大专项助力健康“一带一路”——“‘一带一路’重要传染病流行规律和预警应对技术研究”项目简介[J]. 病毒学报, 35(02)(2019), 351-355.
57. 甄维, 蔡琨, 史海月, 张靖, 韩卫芳, 周为民, **武桂珍**. BSL-3 实验室医疗废弃物专用包装袋的封口方式及层数对高压灭菌效果的影响[J]. 中华实验和临床病毒学杂志, (01)(2019), 30-33.
58. 李婕, 马江涛, 刘俐, 张勇, 冀天娇, 许文波, 严冬梅, **武桂珍**. 2016—2017 年宁夏手足口病的病原构成及流行的 EV-A71 和 CV-A16 基因特征分析[J]. 中华实验和临床病毒学杂志, (01)(2019), 10-15.
59. 周豪, 夏冬, 夏志强, 宋娟, 宋芹芹, 史冰田, 刘宓, 刘露, **武桂珍**, 韩俊. 鼻病毒全球研究现状分析 [J]. 中华实验和临床病毒学杂志, 32(04)(2018), :411-415.
60. 李洁, **武桂珍**. 基于 GoPubMed 对埃博拉病毒研究文献的数据分析[J]. 病毒学报, 34(04)(2018):565-569.
61. 李洁, 韩俊, **武桂珍**. 病毒学实验室质量管理体系的建立[J]. 病毒学报, 34(03)(2018), 390-394. (通讯作者)
62. 李洁, 韩俊, **武桂珍**. 国家级病毒学实验室资质认定特点分析[J]. 病毒学报, 34(03)(2018), 386-389.
63. 魏强, **武桂珍**. 新时代的中国病原微生物实验室生物安全工作思考[J]. 中华实验和临床病毒学杂志, 32(02)(2018):113-115.
64. 李洁, 何小周, 杨梦婕, 马学军, **武桂珍**. 病毒学实验室资质认定中非标方法的确认研究[J]. 中华实验和临床病毒学杂志, 32(02)(2018), 211-213.
65. 王衍海, 宋庆华, 王世文, 韩俊, **武桂珍**. 病原微生物菌(毒)种库防护对策研究[J]. 生物技术通讯, 29(02)(2018), 277-280.
66. 甄维, 刘宓, 张靖, 蔡琨, 张曙霞, 韩卫芳, 周为民, **武桂珍**. 适用于生物安全三级实验室的口罩的适合性影响因素[J]. 中华实验和临床病毒学杂志, 31(02)(2017):172-175.
67. 王芹, 张勇, 聂凯, 王环宇, 杜海军, 宋敬东, 肖康, 雷雯雯, 郭建强, 隗合江, 蔡琨, 王衍海, 吴江, Gerald Bangura, Idrissa Laybohr Kamara, 梁米芳, **武桂珍**, 董小平. 中塞友好生物安全实验室埃博拉病毒核酸检测质量控制体系的建立[J]. 病毒学报, 32(02)(2016), 210-214.
68. 陆柔剑, 武婕, 牛培华, 赵彦杰, 周为民, 邹丽容, 王慧娟, 李辉, 柯昌文, **武桂珍**, 谭文杰. 中国首例输入性中东呼吸综合征病例实验室确诊方法比较[J]. 中华实验和临床病毒学杂志, 29(03)(2015), 193-195.
69. 刘晓宇, 李思思, 赵赤鸿, **武桂珍**. 全国 22 省(市)负压生物安全二级实验室建设现况的调查分析[J]. 中国医学装备, 11(01)(2014), 5-8.

70. 魏强, 卢选成, **武桂珍**. 痘苗病毒实验室获得性感染病例的状况及特征分析[J]. 中华实验和临床病毒学杂志, (01)(2013), 73-75.
71. 魏强, **武桂珍**. 美国与欧洲实验室生物安全专业能力要求的对比分析[J]. 军事医学, 37(01)(2013), 43-46.
72. 李晓燕, 卢选成, 李春雨, **武桂珍**. 生物安全二级动物实验室的个人防护[J]. 中国医学装备, 9(04)(2012), 39-41.
73. 姜孟楠, 赵赤鸿, 李春雨, 卢选成, **武桂珍**. 感染性物质运输的研究与实践[J]. 中国医学装备, 9(03)(2012), 1-3.
74. 李春雨, 李晓燕, 姜孟楠, 卢选成, **武桂珍**. 感染性动物解剖室的风险因素分析及其控制策略的研究[J]. 中国医学装备, 9(02)(2012), 1-3.
75. 魏强, 李晓燕, 王雷, 卢选成, 姜孟楠, **武桂珍**, 侯培森. 近年病原微生物实验室获得性感染病例分析及其控制策略的初步研究[J]. 中华实验和临床病毒学杂志, (05)(2011), 390-392.
76. 李晓燕, 卢选成, **武桂珍**. 非人灵长类动物感染性实验生物风险分析[J]. 中国公共卫生管理, 27(05)(2011), 482-483.
77. 胡寒雁, 王衍海, 张瑶, 贾淑惠, 韩卫芳, 高云雪, 韩俊, **武桂珍**. 病原微生物实验室生物安全和管理的关系探讨[J]. 中国卫生检验杂志, 21(08)(2011), 074-2076.
78. 王衍海, 王大燕, 胡寒雁, 王雷, 徐翠玲, 魏强, **武桂珍**, 韩俊. 甲型 H1N1 流感病毒实验室风险评估[J]. 中国公共卫生, 27(01)(2011), 33-34.
79. 王雷, **武桂珍**. 病原微生物材料安全数据单应用进展[J]. 中华实验和临床病毒学杂志, (04)(2010), 320-321.
80. 李媛, 梅国勇, 姜慧英, 王桂荣, 魏强, 韩露, 王雷, 田婵, 韩卫芳, **武桂珍**, 王克霞, 韩俊. 病毒学实验室的溢洒现象研究[J]. 中华实验和临床病毒学杂志, (06)(2009), 458-460.
81. 李晓燕, 姜孟楠, 卢选成, 肖革新, **武桂珍**. 实验用猕猴质量控制信息系统设计与开发研究[J]. 中国比较医学杂志, 19(04)(2009), 78-82.
82. 魏强, **武桂珍**, 侯培森. 医学病原微生物菌(毒)种的保藏管理[J]. 中华预防医学杂志, 2009(04), 331-332.
83. 王雷, **武桂珍**. 中国疾控系统实验室信息管理系统建设需求分析[J]. 中国公共卫生管理, 26(02)(2010), 122-124.
84. 周永运, **武桂珍**. 建立化学实验室安全管理体系[J]. 中国公共卫生管理, 25(03)(2009), 325-326.
85. 李媛, 梅国勇, 姜慧英, 王桂荣, 田婵, 韩露, 韩卫芳, 魏强, 周永运, **武桂珍**, 王克霞, 韩俊. 两种模式病毒灭活风险实验研究[J]. 中华实验和临床病毒学杂志, (05)(2008), 327-329.
86. 魏强, **武桂珍**. 中国疾病预防控制中心实验室信息管理系统的建设与管理[J]. 疾病监测, (10)(2008), 599-601.

4.1.2 第一（含共同）作者论文

1. Geng J, Chen L, Yuan Y, Wang K, Wang Y, Qin C, **Wu G**, Chen R, Zhang Z, Wei D, Du P, Zhang J, Lin P, Zhang K, Deng Y, Xu K, Liu J, Sun X, Guo T, Yang X,

- Wu J, Jiang J, Li L, Zhang K, Wang Z, Zhang J, Yan Q, Zhu H, Zheng Z, Miao J, Fu X, Yang F, Chen X, Tang H, Zhang Y, Shi Y, Zhu Y, Pei Z, Huo F, Liang X, Wang Y, Wang Q, Xie W, Li Y, Shi M, Bian H, Zhu P, Chen ZN. CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma. *Signal Transduct Target Ther*, 6(1) (2021), 347, doi: 10.1038/s41392-021-00760-8.
- Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, **Wu G**, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W, Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo W, Yang X. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. *Lancet Infect Dis*, 21(1) (2021), 39-51, doi: 10.1016/S1473-3099(20)30831-8.
 - 潘俊宇, **武桂珍**. 侯云德院士及其团队的专利成果分析[J]. *中国发明与专利*, 15(02) (2018), 8-14.
 - 武桂珍**. 致敬—2017 年国家最高科学技术奖获奖者侯云德院士[J]. *病毒学报*, 34(01) (2018), 145-146.
 - 武桂珍**. 主编寄语[J]. *中华实验和临床病毒学杂志*, 31(01) (2017), 1.
 - 武桂珍**. 我国病原微生物实验室生物安全风险控制和管理体系的构建及应用. 北京市, 中国疾病预防控制中心病毒病预防控制所, 2015-04-15.
 - 武桂珍**. 安全使用 保护资源——《人间传染的病原微生物菌(毒)种保藏机构设置技术规范》解读[J]. *中国卫生标准管理*, 1(03) (2010), 43-44.
 - 武桂珍**, 陈明亭, 魏承毓. 生物恐怖的特点与应对措施[J]. *疾病监测*, (10) (2002), 391-394.
 - 武桂珍**, 贾志远, 黄玉英, 龚晓红, 李燕婷, 李守邦, 杨超美, 刘建地, 李敏, 李志仁, 曹惠霖. 城、郊新生儿乙型肝炎疫苗免疫情况调查[J]. *中华流行病学杂志*, (05) (1999), 29-32.
 - 武桂珍**. 卫生部肝炎防治专家咨询委员会第四次会议在北京召开[J]. *疾病监测*, (07)(1998), 37-38.
 - 武桂珍**, 苏崇鳌. 接种乙型肝炎疫苗是预防乙型肝炎的最有效手段[J]. *预防医学情报杂志*, (02) (1997), 31.
 - 武桂珍**. 全国病毒性肝炎防治对策研讨会在北京召开[J]. *疾病监测*, (03) (1996), 117-118.
 - 武桂珍**, 苏崇鳌. 1991 年度全国传染病疫情分析会在天津召开[J]. *疾病监测*, (06) (1992), 163.
 - 武桂珍**. 全国推广使用乙肝疫苗接种工作现场会在湘潭市召开[J]. *疾病监测*, (01) (1992), 23.

4.1.3 合作作者论文

- Huang B, Zhao H, Song J, Zhao L, Deng Y, Wang W, Lu R, Wang W, Ren J, Ye F, Tian H, **Wu G**, Ling H, Tan W. Isolation and Characterization of Monkeypox

- Virus from the First Case of Monkeypox - Chongqing Municipality, China, 2022. *China CDC Wkly*, 4(46) (2022), 1019-1024, doi: 10.46234/ccdcw2022.206.
2. Wu Z, Jin Q, **Wu G**, Lu J, Li M, Guo D, Lan K, Feng L, Qian Z, Ren L, Tan W, Xu W, Yang W, Wang J, Wang C. SARS-CoV-2's origin should be investigated worldwide for pandemic prevention. *Lancet*, 398(10308) (2021), 1299-1303, doi: 10.1016/S0140-6736(21)02020-1.
 3. Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, **Wu G**, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang W, Zhang W, Li N, Xie Z, Zhu X, Ding L, You W, Zhao Y, Zhao J, Huang L, Shi X, Yang Y, Xu G, Wang W, Liu P, Ma M, Qiao Y, Zhao S, Chai J, Li Q, Fu H, Xu Y, Zheng X, Guo W, Yang X. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. *Lancet Infect Dis*, 21(1) (2021), 39-51, doi: 10.1016/S1473-3099(20)30831-8.
 4. Li X, Wang L, Liu P, Li H, Huo S, Zong K, Zhu S, Guo Y, Zhang L, Hu B, Lan Y, Chmura A, **Wu G**, Daszak P, Liu WJ, Gao GF. A novel potentially recombinant rodent coronavirus with a polybasic cleavage site in the spike protein. *J Virol*, 95(22) (2021), e0117321, doi: 10.1128/JVI.01173-21.
 5. Yang P, Zhao Y, Li J, Liu C, Zhu L, Zhang J, Yu Y, Wang WJ, Lei G, Yan J, Sun F, Bian C, Meng F, Xu Z, Bai C, Ye B, Guo Y, Shu L, Yuan X, Zhang N, Bi Y, Shi Y, **Wu G**, Zhang S, Gao GF, Liu L, Liu WJ, Sun HX. Downregulated miR-451a as a feature of the plasma cfRNA landscape reveals regulatory networks of IL-6/IL-6R-associated cytokine storms in COVID-19 patients. *Cell Mol Immunol*, 18(4) (2021), 1064–1066, doi: 10.1038/s41423-021-00652-5.
 6. Yang J, Niu P, Chen L, Wang L, Zhao L, Huang B, Ma J, Hu S, Wu L, **Wu G**, Huang C, Bi Y, Tan W. Genetic tracing of HCoV-19 for the re-emerging outbreak of COVID-19 in Beijing, China. *Protein Cell*, 12(1)(2021), 4–6, doi: 10.1007/s13238-020-00772-0.
 7. Sun H, Li Y, Liu P, Qiao C, Wang X, Wu L, Liu K, Hu Y, Su C, Tan S, Zou S, **Wu G**, Yan J, Gao GF, Qi J, Wang Q. Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry. *Emerg Microbes Infect*, 9(1) (2020), 1238-1241, doi: 10.1080/22221751.2020.1770631.
 8. Zhu N, Wang W, Liu Z, Liang C, Wang W, Ye F, Huang B, Zhao L, Wang H, Zhou W, Deng Y, Mao L, Su C, Qiang G, Jiang T, Zhao J, **Wu G**, Song J, Tan W. 2020. Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells. *Nat Commun*, 11(1) (2020), 3910, doi: 10.1038/s41467-020-17796-z.
 9. Zhu L, Yang P, Zhao Y, Zhuang Z, Wang Z, Song R, Zhang J, Liu C, Gao Q, Xu Q, Wei X, Sun HX, Ye B, Wu Y, Zhang N, Lei G, Yu L, Yan J, Diao G, Meng F, Bai C, Mao P, Yu Y, Wang M, Yuan Y, Deng Q, Li Z, Huang Y, Hu G, Liu Y, Wang X, Xu Z, Liu P, Bi Y, Shi Y, Zhang S, Chen Z, Wang J, Xu X, **Wu G**, Wang FS, Gao GF, Liu L, Liu WJ. 2020. Single-Cell Sequencing of Peripheral Mononuclear Cells Reveals Distinct Immune Response Landscapes of COVID-19 and Influenza Patients. *Immunity*, 53(3) (2020), 685-696, doi: 10.1016/j.immuni.2020.07.009.

10. Zhou L, Wu Z, Li Z, Zhang Y, McGoogan JM, Li Q, Dong X, Ren R, Feng L, Qi X, Xi J, Cui Y, Tan W, Shi G, **Wu G**, Xu W, Wang X, Ma J, Su X, Feng Z, Gao GF, China C-TF. 2020. One Hundred Days of Coronavirus Disease 2019 Prevention and Control in China. *Clin Infect Dis*, 72(2)(2021), 332-339, doi: 10.1093/cid/ciaa725.
11. Yu P, Qi F, Xu Y, Li F, Liu P, Liu J, Bao L, Deng W, Gao H, Xiang Z, Xiao C, Lv Q, Gong S, Liu J, Song Z, Qu Y, Xue J, Wei Q, Liu M, Wang G, Wang S, Yu H, Liu X, Huang B, Wang W, Zhao L, Wang H, Ye F, Zhou W, Zhen W, Han J, **Wu G**, Jin Q, Wang J, Tan W, Qin C. 2020. Age-related rhesus macaque models of COVID-19. *Animal Model Exp Med*, 3(1) (2020),93-97, doi: 10.1002/ame2.12108..
12. Wang Y, Liu D, Shi W, Lu R, Wang W, Zhao Y, Deng Y, Zhou W, Ren H, Wu J, Wang Y, **Wu G**, Gao GF, Tan W. 2017. A47 Origin and possible genetic recombination of the middle east respiratory syndrome coronavirus from the first imported case in china: phylogenetics and coalescence analysis. *Virus Evol*, 3(1) (2017):vew036-046, doi: 10.1093/ve/vew036.046.
13. Zhang S, Yu JL, He L, Gong L, Hou S, Zhu M, Wu JB, Su B, Liu J, **Wu G**, He J. Molecular characteristics of the H9N2 avian influenza viruses in live poultry markets in Anhui Province, China, 2013 to 2018. *Health Sci Rep*, 4(1)(2021), e230, doi: 10.1002/hsr2.230.
14. Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, Song T, Bi X, Han C, Wu L, Gao G, Hu X, Zhang Y, Tong Z, Huang W, Liu WJ, **Wu G**, Zhang B, Wang L, Qi J, Feng H, Wang FS, Wang Q, Gao GF, Yuan Z, Yan J.A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. *Nature*, 584(7819) (2020), 120-124, doi: 10.1038/s41586-020-2381-y.
15. Tian W, Zhang N, Jin R, Feng Y, Wang S, Gao S, Gao R, Wu G, Tian D, Tan W, Chen Y, Gao GF, Wong CCL. Immune suppression in the early stage of COVID-19 disease. *Nat Commun*, 11(1)(2020), 58-59, doi: 10.1038/s41467-020-19706-9.
16. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *Jama*, 323(18) (2020), 1843-1844, doi: 10.1001/jama.2020.3786. Wang W, Xu Y, Gao R, Lu R, Han K, **Wu G**, Tan W. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *Jama*, 323(18)(2020), p. 1843-1844, doi: 10.1001/jama.2020.3786.
17. Wu Y, Wang F, Shen C, Peng W, Li D, Zhao C, Li Z, Li S, Bi Y, Yang Y, Gong Y, Xiao H, Fan Z, Tan S, **Wu G**, Tan W, Lu X, Fan C, Wang Q, Liu Y, Zhang C, Qi J, Gao GF, Gao F, Liu L. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. *Science*, 368(6496)(2020), p. 1274-1278, doi.org/10.1126/science.abc2241.
18. **Wu, G**. Laboratory biosafety in China: past, present, and future. *Biosaf Health*, 1(2)(2019), p. 56-58, doi: 10.1016/j.bshealth.2019.10.003.
19. Liu WJ, Shi W, Zhu W, Jin C, Zou S, Wang J, Ke Y, Li X, Liu M, Hu T, Fan H, Tong Y, Zhao X, Chen W, Zhao Y, Liu D, Wong G, Chen C, Geng C, Xie W, Jiang H, Kamara IL, Kamara A, Lebby M, Kargbo B, Qiu X, Wang Y, Liang X, Liang

- M, Dong X, **Wu G**, Gao GF, Shu Y. Intra-host Ebola viral adaption during human infection. *Biosaf Health*, 1(1)(2019), p. 14-24, doi: 10.1016/j.bsheal.2019.02.001.
20. Ye F, Song J, Zhao L, Zhang Y, Xia L, Zhu L, Kamara IL, Ren J, Wang W, Tian H, **Wu G**, Tan W. Molecular Evidence of Human Monkeypox Virus Infection, Sierra Leone. *Emerg Infect Dis*, 25(6)(2019), 1220-1222, doi: 10.3201/eid2506.180296.
 21. Liu WJ, Sesay FR, Coursier A, Knust B, Marrinan JE, Whitmer S, McDonald SLR, Gaillard P, Liu Y, Su Q, Zhang Y, Crozier I, Ariyarajah A, Carino M, Massaquoi T, Broutet N, Xu W, **Wu G**, Ströcher U, Gao GF, Formenty P, Sahr F, Deen GF. Sierra Leone Ebola Virus Persistence Study Group. Comprehensive Clinical and Laboratory Follow-up of a Female Patient With Ebola Virus Disease: Sierra Leone Ebola Virus Persistence Study. *Open Forum Infect Dis*, 6(3)(2019), p. ofz068, doi: 10.1093/ofid/ofz068.
 22. Liu WJ, Hu HY, Su QD, Zhang Z, Liu Y, Sun YL, Yang XD, Sun DP, Cai SJ, Yang XX, Kamara I, Kamara A, Lebby M, Kargbo B, Ongpin P, Dong XP, Shu YL, Xu WB, **Wu GZ**, Gboun M, Gao GF. HIV prevalence in suspected Ebola cases during the 2014-2016 Ebola epidemic in Sierra Leone. *Infect Dis Poverty*, 8(1) (2019), p. 15, doi: 10.1186/s40249-019-0525-9.
 23. Liu Y, Sun Y, Wu W, Li A, Yang X, Zhang S, Li C, Su Q, Cai S, Sun D, Hu H, Zhang Z, Yang X, Kamara I, Koroma S, Bangura G, Tia A, Kamara A, Lebby M, Kargbo B, Li J, Wang S, Dong X, Shu Y, Xu W, Gao GF, **Wu G**, Li D, Liu WJ, Liang M. Serological Investigation of Laboratory-Confirmed and Suspected Ebola Virus Disease Patients During the Late Phase of the Ebola Outbreak in Sierra Leone. *Virol Sin*, 33(4)(2018), p. 323-334, doi: 10.1007/s12250-018-0044-z.
 24. Zhao M, Liu K, Luo J, Tan S, Quan C, Zhang S, Chai Y, Qi J, Li Y, Bi Y, Xiao H, Wong G, Zhou J, Jiang T, Liu W, Yu H, Yan J, Liu Y, Shu Y, **Wu G**, Wu A, Gao GF, Liu WJ. Heterosubtypic Protections against Human-Infecting Avian Influenza Viruses Correlate to Biased Cross-T-Cell Responses. *MBio*, 9(4)(2018), pii: e01408-18, doi: 10.1128/mBio.01408-18.
 25. Liu WJ, Zou R, Hu Y, Zhao M, Quan C, Tan S, Luo K, Yuan J, Zheng H, Liu J, Liu M, Bi Y, Yan J, Zhu B, Wang D, **Wu G**, Liu L, Yuen KY, Gao GF, Liu Y. Clinical, immunological and bacteriological characteristics of H7N9 patients nosocomially co-infected by *Acinetobacter Baumannii*: a case control study. *BMC Infect Dis*, 18(1)(2018), p. 664, doi: 10.1186/s12879-018-3447-4.
 26. Tan S, Zhang S, Wu B, Zhao Y, Zhang W, Han M, Wu Y, Shi G, Liu Y, Yan J, **Wu G**, Wang H, Gao GF, Zhu F, Liu WJ. Hemagglutinin-specific CD4(+) T-cell responses following 2009-pH1N1 inactivated split-vaccine inoculation in humans. *Vaccine*, 35(42)(2017), p. 5644-5652, doi: 10.1016/j.vaccine.2017.08.061.
 27. Liu J, Sun Y, Shi W, Tan S, Pan Y, Cui S, Zhang Q, Dou X, Lv Y, Li X, Li X, Chen L, Quan C, Wang Q, Zhao Y, Lv Q, Hua W, Zeng H, Chen Z, Xiong H, Jiang C, Pang X, Zhang F, Liang M, **Wu G**, Gao GF, Liu WJ, Li A, Wang Q. The first imported case of Rift Valley fever in China reveals a genetic reassortment of different viral lineage. *Emerg Microbes Infect*, 6(1)(2017), p. e4, doi: 10.1038/emi.2016.136.

28. Deen GF, Broutet N, Xu W, Knust B, Sesay FR, McDonald SLR, Ervin E, Marrinan JE, Gaillard P, Habib N, Liu H, Liu W, Thorson AE, Yamba F, Massaquoi TA, James F, Ariyaratna A, Ross C, Bernstein K, Coursier A, Klana J, Carino M, Wurie AH, Zhang Y, Dumbuya MS, Abad N, Idriss B, Wi T, Bennett SD, Davies T, Ebrahim FK, Meites E, Naidoo D, Smith SJ, Ongpin P, Malik T, Banerjee A, Erickson BR, Liu Y, Liu Y, Xu K, Brault A, Durski KN, Winter J, Sealy T, Nichol ST, Lamunu M, Bangura J, Landoulsi S, Jambai A, Morgan O, **Wu G**, Liang M, Su Q, Lan Y, Hao Y, Formenty P, Ströcher U, Sahr F. Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors - Final Report. *N Engl J Med*, 377(15)(2017), 1428-1437, doi: 10.1056/NEJMoa1511410.
29. Liu WJ, Tan S, Zhao M, Quan C, Bi Y, Wu Y, Zhang S, Zhang H, Xiao H, Qi J, Yan J, Liu W, Yu H, Shu Y, **Wu G**, Gao GF. Cross-immunity Against Avian Influenza A(H7N9) Virus in the Healthy Population Is Affected by Antigenicity-Dependent Substitutions. *J Infect Dis*, 214(12)(2016), p. 1937-1946, doi: 10.1093/infdis/jiw471.
30. an M, Gao R, Lv Q, Huang S, Zhou Z, Yang L, Li X, Zhao X, Zou X, Tong W, Mao S, Zou S, Bo H, Zhu X, Liu L, Yuan H, Zhang M, Wang D, Li Z, Zhao W, Ma M, Li Y, Li T, Yang H, Xu J, Zhou L, Zhou X, Tang W, Song Y, Chen T, Bai T, Zhou J, Wang D, **Wu G**, Li D, Feng Z, Gao GF, Wang Y, He S, Shu Y. Human infection with a novel, highly pathogenic avian influenza A (H5N6) virus: Virological and clinical findings. *J Infect*, 72(1)(2016), p. 52-9, doi: 10.1016/j.jinf.2015.06.009.
31. Wang W, Wang H, Deng Y, Song T, Lan J, **Wu G**, Ke C, Tan W. Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an imported case in China. *Emerg Microbes Infect*, 5(11)(2016), p. e113, doi: 10.1038/emi.2016.114.
32. Wu D, Zou S, Bai T, Li J, Zhao X, Yang L, Liu H, Li X, Yang X, Xin L, Xu S, Zou X, Li X, Wang A, Guo J, Sun B, Huang W, Zhang Y, Li X, Gao R, Shen B, Chen T, Dong J, Wei H, Wang S, Li Q, Li D, **Wu G**, Feng Z, Gao GF, Wang Y, Wang D, Fan M, Shu Y. Poultry farms as a source of avian influenza A (H7N9) virus reassortment and human infection. *Sci Rep*, 5(2015), p. 7630, doi: 10.1038/srep07630.
33. Wang Y, Liu D, Shi W, Lu R, Wang W, Zhao Y, Deng Y, Zhou W, Ren H, Wu J, Wang Y, **Wu G**, Gao GF, Tan W. Origin and Possible Genetic Recombination of the Middle East Respiratory Syndrome Coronavirus from the First Imported Case in China: Phylogenetics and Coalescence Analysis. *mBio*, 6(5)(2015), p. e01280-15, doi: 10.1128/mBio.01280-15.
34. Lu R, Wang Y, Wang W, Nie K, Zhao Y, Su J, Deng Y, Zhou W, Li Y, Wang H, Wang W, Ke C, Ma X, **Wu G**, Tan W. Complete Genome Sequence of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) from the First Imported MERS-CoV Case in China. *Genome Announc*, 3(4)(2015), doi: 10.1128/genomeA.00818-15.
35. Liu M, Li X, Yuan H, Zhou J, Wu J, Bo H, Xia W, Xiong Y, Yang L, Gao R, Guo J, Huang W, Zhang Y, Zhao X, Zou X, Chen T, Wang D, Li Q, Wang S, Chen S,

- Hu M, Ni X, Gong T, Shi Y, Li J, Zhou J, Cai J, Xiao Z, Zhang W, Sun J, Li D, **Wu G**, Feng Z, Wang Y, Chen H, Shu Y. Genetic diversity of avian influenza A (H10N8) virus in live poultry markets and its association with human infections in China. *Sci Rep*, 5(2015), p. 7632, doi: 10.1038/srep07632.
36. Chen H, Yuan H, Gao R, Zhang J, Wang D, Xiong Y, Fan G, Yang F, Li X, Zhou J, Zou S, Yang L, Chen T, Dong L, Bo H, Zhao X, Zhang Y, Lan Y, Bai T, Dong J, Li Q, Wang S, Zhang Y, Li H, Gong T, Shi Y, Ni X, Li J, Zhou J, Fan J, Wu J, Zhou X, Hu M, Wan J, Yang W, Li D, **Wu G**, Feng Z, Gao GF, Wang Y, Jin Q, Liu M, Shu Y. Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study. *Lancet*, 383(9918)(2014), p. 714-21, doi: 10.1016/S0140-6736(14)60111-2.
37. Zhou J, Wang D, Gao R, Zhao B, Song J, Qi X, Zhang Y, Shi Y, Yang L, Zhu W, Bai T, Qin K, Lan Y, Zou S, Guo J, Dong J, Dong L, Zhang Y, Wei H, Li X, Lu J, Liu L, Zhao X, Li X, Huang W, Wen L, Bo H, Xin L, Chen Y, Xu C, Pei Y, Yang Y, Zhang X, Wang S, Feng Z, Han J, Yang W, Gao GF, **Wu G**, Li D, Wang Y, Shu Y. Biological features of novel avian influenza A (H7N9) virus. *Nature*, 499(7459)(2013), 500-502, doi: 10.1038/nature12379.
38. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, Xu X, Lu H, Zhu W, Gao Z, Xiang N, Shen Y, He Z, Gu Y, Zhang Z, Yang Y, Zhao X, Zhou L, Li X, Zou S, Zhang Y, Li X, Yang L, Guo J, Dong J, Li Q, Dong L, Zhu Y, Bai T, Wang S, Hao P, Yang W, Zhang Y, Han J, Yu H, Li D, Gao GF, **Wu G**, Wang Y, Yuan Z, Shu Y. Human infection with a novel avian-origin influenza A (H7N9) virus. *N Engl J Med*, 368(20)(2013), p. 1888-97, doi: 10.1056/NEJMoa1304459.
39. Wang XL, Song J, Song QQ, Yu J, Luo XN, **Wu GZ**, Han J. Viral Contamination Source in Clinical Microbiology Laboratory. *Biomedical and Environmental Sciences*, 29(8)(2016), Pages 609-611, doi: 10.3967/bes2016.082.
40. Wang WL, Wang HJ, Deng Y, Song T, Lan JM, **Wu GZ**, Ke CW, Tan WJ. Serological Study of An Imported Case of Middle East Respiratory Syndrome and His Close Contacts in China, 2015. *BIOMEDICAL AND ENVIRONMENTAL SCIENCES*, 29(3)(2016), 219-223, doi: 10.3967/bes2016.027.
41. Sun YS, Zhao XY, Zhang BK, Jiang JF, Lu HJ, Cao YX, **Wu GZ**, Qian J, Sun YS, Zeng YJ. Practices and thinking of laboratory detection in the aid to West Africa to fight against Ebola. *BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY*, 117(5)(2016), 254-257, doi: 10.4149/bll_2016_049.
42. 朱娜,谭文杰,**武桂珍**,高福. 类器官技术在新型冠状病毒病原快速发现与研究中的创新应用[J]. *科学观察*, 17(06)(2022), 36-40.
43. T/CPMA 019-2020 新型冠状病毒样本保藏要求[J]. *中国病毒病杂志*, 11(02)(2021), 81-86.
44. 邱丰,周为民,尹文娇,周文亭,曹经瑗,毕胜利,**武桂珍**. 不同消毒剂对 HBV 核酸和表面抗原的作用效果研究[J]. *医学研究杂志*, 49(05)(2020), 69-72.
45. 张曙霞,凌云,**武桂珍**,卢洪洲. 国内外高等级隔离病房技术规范比较[J], *中华*

实验和临床病毒学杂志, (05)(2019), 547-550.

46. 吴东林,邹淑梅,白天,李静,赵翔,杨磊,柳鸿敏,李晓丹,杨显达,辛丽,许爽,邹晓辉,李希妍,王岙,郭俊峰,孙炳新,黄维娟,张焯,李响,高荣保,沈博,陈涛,董婕,隗合江,王世文,李群,李德新,武桂珍,冯子健,高福,王宇,王大燕,范明,舒跃龙. 家禽养殖场是H7N9禽流感病毒的重配场所及人类的传染源[A]. 吉林科学技术出版社. 2016-2017年吉林省自然科学学术成果奖汇集[C]:吉林省科学技术协会学会学术部, (2019), 150-156.
47. 叶飞,宋敬东,赵莉,张益,夏连续,祝令伟,任娇,王文玲,武桂珍,田厚文,谭文杰. 分子与血清学检测确诊2017年西非塞拉利昂1例猴痘病毒感染病例[J]. 中国人兽共患病学报, 35(06)(2019), 535-538.
48. 夏冬,宋娟,罗小暖,宋芹芹,王欣玲,武桂珍,韩俊. 建立荧光定量PCR方法鉴定1例入境人员携带伊科普玛病毒基因[J]. 中华实验和临床病毒学杂志, 31(05)(2017), 454-456.
49. 王慧娟,王文玲,蓝佳明,宋铁,甄维,周为民,柯昌文,武桂珍,谭文杰. 基于全病毒颗粒的中东呼吸综合征冠状病毒抗体检测方法的建立[J]. 中华微生物学和免疫学杂志, 36(02)(2016), 93-97.
50. GB 27421-2015, 移动式实验室生物安全要求[S].
51. 陆柔剑,邹丽容,王延群,赵彦杰,周为民,武婕,王文玲,武桂珍,柯昌文,谭文杰. 中国首例输入性中东呼吸综合征冠状病毒结构基因与附属基因的序列分析[J]. 病毒学报, 31(04)(2015), 333-340.
52. 刘艳,武桂珍,王珑. 实验动物设施感染案例分析及控制对策[J]. 中国公共卫生管理, 28(02)(2012), 128-129.
53. 李晓燕,卢选成,刘艳,武桂珍. 实验动物管理工作中动物福利的重要性及影响动物福利的重要因素[J]. 实验动物科学, 28(03)(2011), 74-77.
54. 王雷,魏强,李春雨,武桂珍. 病原微生物材料安全数据单编写研究[J]. 中国公共卫生管理, 27(02)(2011), 125-127.
55. 杨维中,张静,白呼群,苏崇鳌,汪诚信,冯子健,王子军,武桂珍,常昭瑞,黄玉英,李培龙,王豫林,贾庆良,汪新丽,毛德强,冯连贵,万时学,罗超,颜朝阳,崔小平,石国生,廖和平,江斌,徐勇,杨小兵,潘会明,贺圆圆,梁国栋,刘起勇,鲁亮,郭玉红. 三峡库区以生物媒介传播疾病为重点的人群健康监测与评估(1997-2009). 北京市,中国疾病预防控制中心, (2011).
56. 卢选成,李晓燕,姜孟楠,武桂珍. 感染性动物实验设施的设计与建设[J]. 中国公共卫生管理, 25(02)(2009), 153-154.
57. 周永运,武桂珍. 加强疾病监测与动态进行人类肠道病毒71型生物风险评估[J]. 中华预防医学杂志,(04)(2009), 328-330.
58. GB 19489-2008, 实验室生物安全通用要求[S].
59. WS 315-2010, 人间传染的病原微生物菌(毒)种保藏机构设置技术规范[S].
60. 吴文化,武桂珍,陈化新,宋干,胡经畚. 宁夏和甘肃肾综合征出血热的考察报告[J]. 中国公共卫生, (01)(1996), 17-19.
61. 贾志远,武桂珍,苏崇鳌,黄玉英,梨燕琴,杨超美,刘建地,扈光伟,刘崇柏. 上海等四城市城区和郊区新生儿乙型肝炎疫苗免疫效果调查[J]. 中国计划免疫, (05)(1999), 258-261.
62. 曹惠霖,武桂珍,贾志远,鄂启顺,董杰,殷文武,李守邦,王建军,朱荣,雷激,周小凤. 1998年水灾后受灾地区甲型肝炎血清流行病学调查[J]. 中国计

划免疫, (05)(1999), 279-282.

63. 张静, **武桂珍**. 国外肠出血性大肠杆菌 O157:H7 感染性疾病的主要监测系统[J]. 疾病监测, (10)(2000), 390-392.
64. 张静, 汪诚信, 白呼群, 苏崇鳌, 鄂启顺, **武桂珍**, 黄玉英. 三峡库区虫媒和自然疫源性疾病的分析[J]. 长江流域资源与环境, (02)(2004), 145-148.
65. 赵赤鸿, **武桂珍**. 实验室安全管理对策浅探[J]. 中国公共卫生管理, (03)(2008), 321-323.

4.2 著作

4.2.1 主编/译著作

1. **武桂珍**, 《国家生物安全学》, 科学出版社, 2023 年 6 月 30 日, 主编。
2. **武桂珍**, 《实验室生物安全能力建设》, 清华大学出版社, 2023 年, 北京市。4 月 10 日, 主编。
3. **武桂珍**, 《二级生物安全实验室设计建造与运行管理指南》, 中国计划出版社, 2021 年, 北京市。
合著, 主编。
4. **武桂珍**, 《实验室生物安全手册》, 人民卫生出版社, 2020 年, 北京市。
合著, 主编。
5. **武桂珍**, 《援非纪行》, 人民卫生出版社, 2018 年, 北京市。
合著, 主编。
6. **武桂珍**, 《病原微生物实验室生物安全词汇》, 人民卫生出版社, 2017 年, 北京市。
合著, 主编。
7. **武桂珍**, 《中国实验室生物安全能力发展报告—科技发展与产出分析》, 人民卫生出版社, 2016 年, 北京市。
合著, 主编。
8. **武桂珍**, 《人间传染的病原微生物菌(毒)种保藏机构设置技术规范理解与实施》, 人民卫生出版社, 2016 年, 北京市。
合著, 主编。
9. **武桂珍**, 《实验室生物安全法律法规汇编》, 军事医学出版社, 2016 年, 北京市。
合著, 主编。
10. **武桂珍**, 英文版《埃博拉病毒检测及个人防护》 ISBN 978-7-88056-689-5, 北京科影音像出版社, 2014 年, 北京市。
合著, 总策划。
11. **武桂珍**, 中文版《埃博拉病毒检测及个人防护》 ISBN 978-7-88056-689-8, 北京科影音像出版社, 2014 年, 北京市。
合著, 总策划。
12. **武桂珍**, 《实验室生物安全个人防护装备基础知识与相关标准》, 军事医学科学出版, 2012 年, 北京市。

- 合著，主编。
13. **武桂珍**，《高致病性病原微生物材料安全数据单》，中国协和医科大学出版社，2011年，北京市。
合著，主编。
 14. **武桂珍**，《高致病性病原微生物危害评估指南》，北京大学医学出版社，2008年，北京市。
合著，主编。
 15. **武桂珍**，《病原微生物实验室生物安全》(DVD教材)，北京科影音像出版社，2007年，北京市。
合著，总编导。
 16. **武桂珍**，《实验动物相关法规标准汇编》，北京大学医学出版社，2009年，北京市。
合著，主编。
 17. **武桂珍**，《化学实验室安全管理相关法律法规资料汇编（国内部分）》，北京大学医学出版社，2008年，北京市。
合著，主编。

4.2.2 合著著作

1. **武桂珍**，《实验室感染事件案例集》，北京大学医学出版社，2007年，北京市。
合著，副主编。
2. **武桂珍**，《实验室生物安全国内外法规标准汇编》，北京大学医学出版社，2006年，北京市。
合著，副主编。
3. **武桂珍**，《加拿大生物安全标准与指南》，科学出版社，2017年，北京市。
合著，审者。
4. **武桂珍**，《化学恐怖应对手册》，北京医科大学出版社，2002年，北京市。
合著，编委。
5. **武桂珍**，《化学与生物的恐怖事件》，北京医科大学出版社，2002年，北京市。
合著，编委。
6. **武桂珍**，《病毒性肝炎咨询指南》，中国科学技术出版社，2000年，北京市。
合著，编委。
7. **武桂珍**，《病毒性肝炎防治手册》，中国医药科技出版社，2000年，北京市。
合著，编委。
8. 《灾害自救互救指导手册》，华夏出版社，2000年，北京市。
合著，编委。
9. **武桂珍**，《中国不明原因突发性公共卫生事件追述（第一集）》，中国医药科技出版社，2000年，北京市。
合著，编委。
10. 《灾区重点传染病与常见病的预防控制》，中国医药科技出版社，2000年，北京市。
合著，编委。
11. **武桂珍**，《中国病毒性肝炎血清流行病学调查（上卷）》科学技术文献出版社，1992-1995年，北京市。

合著，编委。